$0.45
2.57% yesterday
Nasdaq, Oct 31, 09:07 pm CET
ISIN
US52187K1016
Symbol
LPTX

Leap Therapeutics, Inc. Stock price

$0.45
-0.01 1.50% 1M
+0.03 6.96% 6M
-2.43 84.45% YTD
-3.29 88.04% 1Y
-8.06 94.75% 3Y
-18.55 97.65% 5Y
-78.15 99.43% 10Y
-78.15 99.43% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
-0.01 2.57%
ISIN
US52187K1016
Symbol
LPTX
Industry

Key metrics

Basic
Market capitalization
$25.3m
Enterprise Value
$7.2m
Net debt
positive
Cash
$18.1m
Shares outstanding
41.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.4
Financial Health
Equity Ratio
71.4%
Return on Equity
-193.4%
ROCE
-1,090.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-62.3m | -
EBIT
$-62.3m | $-48.3m
Net Income
$-65.7m | $-46.9m
Free Cash Flow
$-60.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
5.3% | -
EBIT
5.3% | 31.1%
Net Income
-8.9% | 30.8%
Free Cash Flow
-20.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.4
Short interest
5.0%
Employees
52
Rev per Employee
$0.0
Show more

Is Leap Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Leap Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Leap Therapeutics, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Leap Therapeutics, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Leap Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
19% 19%
-
- Research and Development Expense 51 51
2% 2%
-
-62 -62
5% 5%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -62 -62
5% 5%
-
Net Profit -66 -66
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Leap Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Leap Therapeutics, Inc. Stock News

Neutral
PRNewsWire
12 days ago
Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1-high CRC patients CAMBRIDGE, Mass. , Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on d...
Neutral
PRNewsWire
23 days ago
CAMBRIDGE, Mass. , Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has closed its previously announced private placement led by Winklevoss Capital raising $58,888,888 in cash to initiate a digital asset treasury strategy.
Neutral
PRNewsWire
26 days ago
CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in cash commitments for a private investment in public equity ("PIPE") offering led by Winklevoss Capital to initiate a digital asset treasury strategy.
More Leap Therapeutics, Inc. News

Company Profile

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Head office United States
CEO Doug Onsi
Employees 52
Founded 2011
Website www.leaptx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today